Shuntaro Morikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shuntaro Morikawa has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Akie Nakamura
Department of Molecular Endocrinology, National Research Institute for Child Health and Development , Tokyo 157-8535
5 shared publications Akie Nakamura
Department of Pediatrics, Hokkaido University Hospital , Sapporo, 060-8648 , Japan
4 shared publications- Fumihiko Urano
Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA
3 shared publications Naoya Kaneko
Department of Pediatrics, Hokkaido University Hospital , Sapporo 060-8648
3 shared publicationsNozomi Hishimura
Department of Pediatrics, Hokkaido University Hospital , Sapporo 060-8648
3 shared publicationsToshihiro Tajima
Department of Pediatrics, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan
3 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Elsevier in Environment International
- Vol. 213, 110353
Impact of prenatal manganese and selenium exposure on childhood thyroid hormone parameters up to 4 years of age: Japan environment and children’s study
- 4 June 2026
- Published by Elsevier in Environment International
- Vol. 213, 110353
Open AccessImpact of prenatal manganese and selenium exposure on childhood thyroid hormone parameters up to 4 years of age: Japan environment and children’s study
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (6) , 729-740
Endocrine disorders in pediatric medulloblastoma survivors treated with X-ray or proton beam therapy: a single-institution retrospective study
Medulloblastoma, a common pediatric central nervous system disease, is managed with surgery, chemotherapy, and craniospinal irradiation (CSI) delivered with either X-rays or protons. Proton-beam CSI, introduced to protect the surrounding tissues, may reduce endocrine toxicity. In this single-institution retrospective observational study, we evaluated adverse endocrine events in 14 patients diagnosed with medulloblastoma before 13 years of age: 9 and 5 received X-ray and proton beam CSI, respectively. In the X-ray therapy group, the median age at diagnosis was 4.2 (range: 1.4–12.5) years, the median post-radiation follow-up was 19.5 (9.7–34.7) years, and the median CSI dose was 25.2 (23.4–36.0) Gy. The proton beam therapy group showed corresponding medians of 9.4 (5.3–11.7) years, 6.9 (5.4–8.1) years, and 23.4 (23.4–36.0) Gy. Five years after radiation therapy completion, the incidence of growth hormone deficiency was 44% (4/9) and 60% (3/5) in the X-ray and proton beam therapy groups, respectively. However, primary hypothyroidism and central hypothyroidism were exclusively observed in the X-ray therapy group, in 33% (3/9) and 11% (1/9) of patients. Given the short follow-up period for the proton beam therapy group, the difference in the occurrence rates of gonadal dysfunction and adrenal insufficiency is currently unknown. Our findings suggest that, at ≤5 years after the completion of radiation therapy, radiation-induced hypothyroidism was observed only in patients treated with X-ray therapy and not in those treated with proton beam therapy. Further studies with larger cohorts and longer follow-up periods are required to clarify this possible advantage and to refine radiation therapy protocols.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (6) , 729-740
Open AccessEndocrine disorders in pediatric medulloblastoma survivors treated with X-ray or proton beam therapy: a single-institution retrospective study
Medulloblastoma, a common pediatric central nervous system disease, is managed with surgery, chemotherapy, and craniospinal irradiation (CSI) delivered with either X-rays or protons. Proton-beam CSI, introduced to protect the surrounding tissues, may reduce endocrine toxicity. In this single-institution retrospective observational study, we evaluated adverse endocrine events in 14 patients diagnosed with medulloblastoma before 13 years of age: 9 and 5 received X-ray and proton beam CSI, respectively. In the X-ray therapy group, the median age at diagnosis was 4.2 (range: 1.4–12.5) years, the median post-radiation follow-up was 19.5 (9.7–34.7) years, and the median CSI dose was 25.2 (23.4–36.0) Gy. The proton beam therapy group showed corresponding medians of 9.4 (5.3–11.7) years, 6.9 (5.4–8.1) years, and 23.4 (23.4–36.0) Gy. Five years after radiation therapy completion, the incidence of growth hormone deficiency was 44% (4/9) and 60% (3/5) in the X-ray and proton beam therapy groups, respectively. However, primary hypothyroidism and central hypothyroidism were exclusively observed in the X-ray therapy group, in 33% (3/9) and 11% (1/9) of patients. Given the short follow-up period for the proton beam therapy group, the difference in the occurrence rates of gonadal dysfunction and adrenal insufficiency is currently unknown. Our findings suggest that, at ≤5 years after the completion of radiation therapy, radiation-induced hypothyroidism was observed only in patients treated with X-ray therapy and not in those treated with proton beam therapy. Further studies with larger cohorts and longer follow-up periods are required to clarify this possible advantage and to refine radiation therapy protocols.
- 19 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (786) , eadp2332
β cell dedifferentiation, the underlying mechanism of diabetes in Wolfram syndrome
Insulin-dependent diabetes in patients with Wolfram syndrome (WS; OMIM 222300) has been linked to endoplasmic reticulum (ER) stress caused by WFS1 gene mutations. However, the pathological process of ER stress–associated β cell failure remains to be fully elucidated. Our results indicate loss of β cell lineage and subsequent dedifferentiation as the mechanisms underlying functional and mass deficits in WS. An immunohistochemical analysis of human pancreatic sections from deceased individuals with WS revealed a near-complete loss of β cells and subsequent decrease in α cells, suggesting loss of endocrine function. Wfs1 -deficient mice displayed dysfunction, gradual loss, and dedifferentiation of β cells, leading to permanent hyperglycemia. Impairment of the β cell lineage was observed after weaning, leading to the mixed phenotype of insulin- and glucagon-producing cells in a subset of the lineage-traced β cells. Islets of Wfs1 -deficient mice increased the number of dedifferentiated cells that maintained general endocrine features but were no longer reactive with antisera against pancreatic hormones. Mechanistically, Wfs1 -null islets had a lower adenosine triphosphate content and impaired oxidative glycolysis, although mitochondrial oxidative function was maintained. The functional and metabolic alterations of WS β cells were recovered by deletion of thioredoxin-interacting protein (Txnip), an ER stress–induced protein up-regulated in Wfs1 deficiency. Txnip deletion preserved functional β cells and prevented diabetes progression in Wfs1 -deficient mice. Together, this study deciphered pathological mechanisms of β cell dedifferentiation in β cell failure and has implications for Txnip inhibition in WS therapy.
- 19 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (786) , eadp2332
β cell dedifferentiation, the underlying mechanism of diabetes in Wolfram syndrome
Insulin-dependent diabetes in patients with Wolfram syndrome (WS; OMIM 222300) has been linked to endoplasmic reticulum (ER) stress caused by WFS1 gene mutations. However, the pathological process of ER stress–associated β cell failure remains to be fully elucidated. Our results indicate loss of β cell lineage and subsequent dedifferentiation as the mechanisms underlying functional and mass deficits in WS. An immunohistochemical analysis of human pancreatic sections from deceased individuals with WS revealed a near-complete loss of β cells and subsequent decrease in α cells, suggesting loss of endocrine function. Wfs1 -deficient mice displayed dysfunction, gradual loss, and dedifferentiation of β cells, leading to permanent hyperglycemia. Impairment of the β cell lineage was observed after weaning, leading to the mixed phenotype of insulin- and glucagon-producing cells in a subset of the lineage-traced β cells. Islets of Wfs1 -deficient mice increased the number of dedifferentiated cells that maintained general endocrine features but were no longer reactive with antisera against pancreatic hormones. Mechanistically, Wfs1 -null islets had a lower adenosine triphosphate content and impaired oxidative glycolysis, although mitochondrial oxidative function was maintained. The functional and metabolic alterations of WS β cells were recovered by deletion of thioredoxin-interacting protein (Txnip), an ER stress–induced protein up-regulated in Wfs1 deficiency. Txnip deletion preserved functional β cells and prevented diabetes progression in Wfs1 -deficient mice. Together, this study deciphered pathological mechanisms of β cell dedifferentiation in β cell failure and has implications for Txnip inhibition in WS therapy.
- Open Access
- 20 January 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (2) , luae220
Skin Reaction to Leuprorelin Acetate
- 20 January 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (2) , luae220
Open AccessSkin Reaction to Leuprorelin Acetate
- Open Access
- 6 April 2024
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 8 (6) , bvae090
Functional Analysis of a Novel HNF4A Variant Identified in a Patient With MODY1
Context HNF4A–maturity-onset diabetes of the young (MODY1) is a relatively rare subtype of monogenic diabetes caused by loss of function of the HNF4A gene, which encodes the transcription factor HNF4α. HNF4α is known to form heterodimers, and the various combinations of isoforms that make up these heterodimers have been reported to result in a diversity of targeted genes. However, the function of individual HNF4α variant isoforms and the heterodimers comprising both wild-type (WT) and variant HNF4α have not yet been assessed. Objective In this study, we analyzed the functional consequence of the HNF4A D248Y variant in vitro. Methods We investigated the case of a 12-year-old Japanese girl who developed diabetes at age 11 years. Genetic sequencing detected a novel heterozygous missense HNF4A variant (c.742G > T, p.Asp248Tyr; referred as “D248Y”) in the patient and her relatives who presented with diabetes. Results Although the WT HNF4α isoforms (HNF4α2, HNF4α3, HNF4α8, HNF4α9) enhanced the INS gene promoter activity in HepG2 cells, the promoter activity of D248Y was consistently low across all isoforms. The presence of D248Y in homodimers and heterodimers, comprising either HNF4α8 or HNF4α3 or a combination of both isoforms, also reduced the INS promoter activity in Panc-1 cells. Conclusion We report the clinical course of a patient with HNF4A-MODY and the functional analysis of novel HNF4A variants, with a focus on the isoforms and heterodimers they form. Our results serve to improve the understanding of the dominant-negative effects of pathogenic HNF4A variants.
- 6 April 2024
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 8 (6) , bvae090
Open AccessFunctional Analysis of a Novel HNF4A Variant Identified in a Patient With MODY1
Context HNF4A–maturity-onset diabetes of the young (MODY1) is a relatively rare subtype of monogenic diabetes caused by loss of function of the HNF4A gene, which encodes the transcription factor HNF4α. HNF4α is known to form heterodimers, and the various combinations of isoforms that make up these heterodimers have been reported to result in a diversity of targeted genes. However, the function of individual HNF4α variant isoforms and the heterodimers comprising both wild-type (WT) and variant HNF4α have not yet been assessed. Objective In this study, we analyzed the functional consequence of the HNF4A D248Y variant in vitro. Methods We investigated the case of a 12-year-old Japanese girl who developed diabetes at age 11 years. Genetic sequencing detected a novel heterozygous missense HNF4A variant (c.742G > T, p.Asp248Tyr; referred as “D248Y”) in the patient and her relatives who presented with diabetes. Results Although the WT HNF4α isoforms (HNF4α2, HNF4α3, HNF4α8, HNF4α9) enhanced the INS gene promoter activity in HepG2 cells, the promoter activity of D248Y was consistently low across all isoforms. The presence of D248Y in homodimers and heterodimers, comprising either HNF4α8 or HNF4α3 or a combination of both isoforms, also reduced the INS promoter activity in Panc-1 cells. Conclusion We report the clinical course of a patient with HNF4A-MODY and the functional analysis of novel HNF4A variants, with a focus on the isoforms and heterodimers they form. Our results serve to improve the understanding of the dominant-negative effects of pathogenic HNF4A variants.
- 13 February 2024
- Published by Springer Nature in Mammalian Genome
- Vol. 35 (1) , 1-12
Comprehensive overview of disease models for Wolfram syndrome: toward effective treatments
Wolfram syndrome (OMIM 222300) is a rare autosomal recessive disease with a devastating array of symptoms, including diabetes mellitus, optic nerve atrophy, diabetes insipidus, hearing loss, and neurological dysfunction. The discovery of the causative gene, WFS1, has propelled research on this disease. However, a comprehensive understanding of the function of WFS1 remains unknown, making the development of effective treatment a pressing challenge. To bridge these knowledge gaps, disease models for Wolfram syndrome are indispensable, and understanding the characteristics of each model is critical. This review will provide a summary of the current knowledge regarding WFS1 function and offer a comprehensive overview of established disease models for Wolfram syndrome, covering animal models such as mice, rats, flies, and zebrafish, along with induced pluripotent stem cell (iPSC)-derived human cellular models. These models replicate key aspects of Wolfram syndrome, contributing to a deeper understanding of its pathogenesis and providing a platform for discovering potential therapeutic approaches.
- 13 February 2024
- Published by Springer Nature in Mammalian Genome
- Vol. 35 (1) , 1-12
Comprehensive overview of disease models for Wolfram syndrome: toward effective treatments
Wolfram syndrome (OMIM 222300) is a rare autosomal recessive disease with a devastating array of symptoms, including diabetes mellitus, optic nerve atrophy, diabetes insipidus, hearing loss, and neurological dysfunction. The discovery of the causative gene, WFS1, has propelled research on this disease. However, a comprehensive understanding of the function of WFS1 remains unknown, making the development of effective treatment a pressing challenge. To bridge these knowledge gaps, disease models for Wolfram syndrome are indispensable, and understanding the characteristics of each model is critical. This review will provide a summary of the current knowledge regarding WFS1 function and offer a comprehensive overview of established disease models for Wolfram syndrome, covering animal models such as mice, rats, flies, and zebrafish, along with induced pluripotent stem cell (iPSC)-derived human cellular models. These models replicate key aspects of Wolfram syndrome, contributing to a deeper understanding of its pathogenesis and providing a platform for discovering potential therapeutic approaches.
- Open Access
- 23 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (1) , 230
The Role of ER Stress in Diabetes: Exploring Pathological Mechanisms Using Wolfram Syndrome
The endoplasmic reticulum (ER) is a cytosolic organelle that plays an essential role in the folding and processing of new secretory proteins, including insulin. The pathogenesis of diabetes, a group of metabolic disorders caused by dysfunctional insulin secretion (Type 1 diabetes, T1DM) or insulin sensitivity (Type 2 diabetes, T2DM), is known to involve the excess accumulation of “poorly folded proteins”, namely, the induction of pathogenic ER stress in pancreatic β-cells. ER stress is known to contribute to the dysfunction of the insulin-producing pancreatic β-cells. T1DM and T2DM are multifactorial diseases, especially T2DM; both environmental and genetic factors are involved in their pathogenesis, making it difficult to create experimental disease models. In recent years, however, the development of induced pluripotent stem cells (iPSCs) and other regenerative technologies has greatly expanded research capabilities, leading to the development of new candidate therapies. In this review, we will discuss the mechanism by which dysregulated ER stress responses contribute to T2DM pathogenesis. Moreover, we describe new treatment methods targeting protein folding and ER stress pathways with a particular focus on pivotal studies of Wolfram syndrome, a monogenic form of syndromic diabetes caused by pathogenic variants in the WFS1 gene, which also leads to ER dysfunction.
- 23 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (1) , 230
Open AccessThe Role of ER Stress in Diabetes: Exploring Pathological Mechanisms Using Wolfram Syndrome
The endoplasmic reticulum (ER) is a cytosolic organelle that plays an essential role in the folding and processing of new secretory proteins, including insulin. The pathogenesis of diabetes, a group of metabolic disorders caused by dysfunctional insulin secretion (Type 1 diabetes, T1DM) or insulin sensitivity (Type 2 diabetes, T2DM), is known to involve the excess accumulation of “poorly folded proteins”, namely, the induction of pathogenic ER stress in pancreatic β-cells. ER stress is known to contribute to the dysfunction of the insulin-producing pancreatic β-cells. T1DM and T2DM are multifactorial diseases, especially T2DM; both environmental and genetic factors are involved in their pathogenesis, making it difficult to create experimental disease models. In recent years, however, the development of induced pluripotent stem cells (iPSCs) and other regenerative technologies has greatly expanded research capabilities, leading to the development of new candidate therapies. In this review, we will discuss the mechanism by which dysregulated ER stress responses contribute to T2DM pathogenesis. Moreover, we describe new treatment methods targeting protein folding and ER stress pathways with a particular focus on pivotal studies of Wolfram syndrome, a monogenic form of syndromic diabetes caused by pathogenic variants in the WFS1 gene, which also leads to ER dysfunction.
- Open Access
- 4 May 2020
- Published by Elsevier in Laboratory Investigation
- Vol. 100 (9) , 1197-1207
A soluble endoplasmic reticulum factor as regenerative therapy for Wolfram syndrome
- 4 May 2020
- Published by Elsevier in Laboratory Investigation
- Vol. 100 (9) , 1197-1207
Open AccessA soluble endoplasmic reticulum factor as regenerative therapy for Wolfram syndrome
- 22 April 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (540)
Gene-edited human stem cell–derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice
Patient stem cell–derived β cells corrected for a diabetes-causing variant in WFS1 restore glucose homeostasis when transplanted into diabetic mice.
- 22 April 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (540)
Gene-edited human stem cell–derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice
Patient stem cell–derived β cells corrected for a diabetes-causing variant in WFS1 restore glucose homeostasis when transplanted into diabetic mice.
- Open Access
- 21 January 2019
- Published by Springer Nature in Human Genome Variation
- Vol. 6 (1) , 7
(Epi)genetic defects of MKRN3 are rare in Asian patients with central precocious puberty
We sequenced MKRN3, the major causative gene of central precocious puberty in Western countries, in 24 Japanese or Chinese patients and examined the DNA methylation and copy-number statuses of this gene in 19 patients. We identified no (epi)genetic defects except for one previously reported mutation. These results, together with reports from Korea, indicate that MKRN3 defects are rare in Asian populations. The ethnic differences likely reflect Western country-specific founder mutations and the rarity of de novo mutations.
- 21 January 2019
- Published by Springer Nature in Human Genome Variation
- Vol. 6 (1) , 7
Open Access(Epi)genetic defects of MKRN3 are rare in Asian patients with central precocious puberty
We sequenced MKRN3, the major causative gene of central precocious puberty in Western countries, in 24 Japanese or Chinese patients and examined the DNA methylation and copy-number statuses of this gene in 19 patients. We identified no (epi)genetic defects except for one previously reported mutation. These results, together with reports from Korea, indicate that MKRN3 defects are rare in Asian populations. The ethnic differences likely reflect Western country-specific founder mutations and the rarity of de novo mutations.